| OCR Text |
Show 84 [47] Stefan P Kastl, Walter S Speidl, Christoph Kaun, Katharina M Katsaros, Gersina Rega, Taras Afonyushkin, Valery N Bochkov, Peter Valent, Afshin Assadian, Georg W Hagmueller, Martina Hoeth, Rainer de Martin, Yongsheng Ma, Gerald Maurer, Kurt Huber, and Johann Wojta. In human macrophages the complement component c5a induces the expression of oncostatin m via AP-1 activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(3):498–503, Mar 2008. [48] Jodie L Simpson, Katherine J Baines, Michael J Boyle, Rodney J Scott, and Peter G Gibson. Oncostatin m (OSM) is increased in asthma with incompletely reversible airflow obstruction. Experimental Lung Research, 35(9):781–794, Nov 2009. [49] Carrie Langdon, Christine Kerr, Li Tong, and Carl D Richards. Oncostatin m regulates eotaxin expression in fibroblasts and eosinophilic inflammation in C57BL/6 mice. Journal of Immunology, 170(1):548–555, Jan 2003. [50] Yong Zhang, Donald Y M Leung, Brittany N Richers, Yusen Liu, Linda K Remigio, David W Riches, and Elena Goleva. Vitamin d inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. Journal of Immunology, 188(5):2127–2135, Mar 2012. [51] Francesco Colotta, Birger Jansson, and Fabrizio Bonelli. Modulation of inflammatory and immune responses by vitamin d. Journal of Autoimmunity, 85:78–97, Dec 2017. [52] Yoshinobu Saito, Arata Azuma, Kuniko Matsuda, Koichiro Kamio, Shinji Abe, and Akihiko Gemma. Pirfenidone exerts a suppressive effect on CCL18 expression in u937-derived macrophages partly by inhibiting STAT6 phosphorylation. Immunopharmacology and Immunotoxicology, 38(6):464–471, Dec 2016. [53] Antje Prasse, Corinna Probst, Elena Bargagli, Gernot Zissel, Galen B Toews, Kevin R Flaherty, Manfred Olschewski, Paola Rottoli, and Joachim Müller-Quernheim. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine, 179(8):717–723, Apr 2009. |